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Abstract
The pipeline for new antibiotics is dry. Despite the creation of public/private
initiatives like Combating Antibiotic Resistant Bacteria Biopharmaceutical
Accelerator (Carb-X) and the Antimicrobial Resistance (AMR) Centre, the
current focus on ‘push-pull’ incentives for the pharmaceutical industry still relies
on economic return. We propose a joint, internationally-funded antimicrobial
development institute that would fund permanent staff to take on roles
previously assigned to pharmaceutical companies. This institute would receive
ring-fenced, long-term, core funding from participating countries as well as
charities, with the aim to focus on transforming the largely dormant
antimicrobial pipeline. Resulting drugs would be sold globally and according to
a principle of shared burdens. Our proposed model for antimicrobial
development aims to maximise society’s investment, through open science,
investment in people, and the sharing of intellectual property.
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The UK’s new five-year national antimicrobial resistance (AMR) 
action plan highlights that society is at a tipping point: not only 
are we running out of effective antibiotics, but the pipeline 
for new drugs is dry and novel diagnostics are slow to come to 
market (HM Government, 2019). Over the past two decades, 
decision-makers have tried to overcome this dry spell by rely-
ing on the market and creating ‘push-pull’ incentives for the 
pharmaceutical industry (Renwick et al., 2016). The fundamen-
tal premise of ‘push-pull’ incentives, is to make it economically 
attractive for major pharmaceutical companies to invest their 
infrastructure, staff and skills into the research, development 
and manufacture of novel antibiotics. The reality for pharmaceu-
tical companies is that there is too little money to be made with 
antibiotics: any new antibiotic will be reserved as a ‘last-line 
defence’, which means it will (hopefully) be an infrequently 
used antibiotic and as such, a poor source of income.
While recent public-private initiatives like Combating Antibi-
otic Resistant Bacteria Biopharmaceutical Accelerator (Carb-X) 
and the AMR Centre (UK), are important steps in the right direc-
tion, we strongly contend that using public funds to support 
private venture and profit is not the only way to refill the antibi-
otic pipeline. In the current model for drug development, the 
tax payer pays for everything up to the point where the pharma-
ceutical companies may invest in later stages of development 
(Galkina Cleary et al., 2018). Society invests in the students, post-
docs, and professors through public funding of the university 
and/or the research grant that pays their salaries and equipment. 
However, at the point where knowledge becomes patentable, it 
quickly disappears down pharmaceutical pipelines.
Commercial pipelines are not always efficient producers of new 
drugs. Potentially promising drugs are abandoned when com-
mercial or global health priorities change. In some cases, pat-
ents are only filed to deter competitors from developing them 
further. Not only are society’s investments in antimicrobial inno-
vation wasted, but the intellectual property associated with a 
drug’s development, i.e., the countless serendipitous leads as 
well as dropped, yet promising, antimicrobials, remain locked-up 
within the private pharmaceutical company—inaccessible to 
the public who invested in the initial development. Ultimately, 
the current mode of subsidised antibiotic development means 
that society pays for 100% of all the drugs that are developed 
and not developed, but, importantly, owns and controls nothing 
(discussed here (Anon, 2019)). It is this obvious disconnect in 
societal investment, which needs to be reformed.
We propose a radical change to the current paradigm of anti-
microbial development and manufacture—one that reflects 
humanity’s shared interests and global health challenges. We pro-
pose a joint, internationally-funded antimicrobial development 
Institute that would fund permanent staff to take on the role 
previously assigned to pharmaceutical companies. This insti-
tute would receive ring-fenced, long-term, core funding from 
participating countries as well as charities, with the aim to focus 
on transforming the largely dormant antimicrobial pipeline.
The international centre would aim to sustainably develop a 
breadth of new antimicrobials to address both immediate and 
emerging global health challenges, respond to needs across organ-
isms, i.e., viral, bacteria, fungal, protist, and develop novel modes 
of action. Prospective antimicrobials submitted to the centre 
would be developed in an open and transparent manner, so that 
innovation can be immediately shared and serendipitous find-
ings can be leveraged by the wider research community. The 
centre would also conduct clinical trials on prospective drug 
candidates, manufacture all antimicrobials through existing generic 
drug manufacturers, and contract research organisations.
Resulting drugs would be sold globally and according to a prin-
ciple of shared burdens. This would mean that high-income 
countries would pay more for research and the drugs themselves 
than low-income countries facing ongoing access problems. 
Signing up to enforceable stewardship requirements would be a 
precondition to receiving new drugs. Since no development 
costs need recouping and no share holder incentives need to be 
satisfied, most drugs could be sold at the cost of manufacture. 
Nearly 40 years of lacking commercial interest in new antibiotic 
development means that our ‘not-for-profit’ antibiotic pipeline 
would not compete with established manufacturers.
A look back at the 20th century shows that our proposed 
approach is not as far-fetched as it may sound. While a turn to 
more profitable ‘lifestyle’ drugs ended pharmaceutical invest-
ment in antibiotic development from the late 1970s onwards 
(Gradmann, 2016), the 1940s saw many of the same companies 
work hand-in-hand with nation states and universities to screen 
antimicrobial compounds, test them in clinical settings, and 
upscale production. There was no patent on penicillin – only on 
the process developed to mass-produce it (Bud, 2009). In the case 
of antimalarials, military interests led to a long history of state- 
directed and subsidized development (Lezaun, 2018). 
Our proposed model for antimicrobial development aims to 
maximise society’s investment, through open science, investment 
in people, and the sharing of intellectual property. Antimicrobial 
resistant infections pose a global challenge. It is time to realise 
that the challenge of solving the global problem of AMR exceeds 
the capacity of commercial actors. We are already financing the 
development of antibiotics, why not collectively own and manage 
the resulting drugs?
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